David R. Liu

Nov 11, 2024 | nature.com | Yunxin Xu |Boxue Tian |Haipeng Gong |David R. Liu |Christopher A. Voigt |B. W. Thuronyi

AbstractDesigning proteins with improved functions requires a deep understanding of how sequence and function are related, a vast space that is hard to explore. The ability to efficiently compress this space by identifying functionally important features is extremely valuable. Here we establish a method called EvoScan to comprehensively segment and scan the high-fitness sequence space to obtain anchor points that capture its essential features, especially in high dimensions.

Dec 18, 2023 | nature.com | Tuan Nguyen |Katherine A. Donovan |Santosh K. Chaudhary |Ananthan Sadagopan |David R. Liu |Benjamin Ebert

AbstractProteolysis-targeting chimeras (PROTACs) are molecules that induce proximity between target proteins and E3 ligases triggering target protein degradation. Pomalidomide, a widely used E3 ligase recruiter in PROTACs, can independently degrade other proteins, including zinc-finger (ZF) proteins, with vital roles in health and disease.

Nov 15, 2023 | nature.com | Intae Moon |Lynette M. Sholl |Kenneth L. Kehl |David R. Liu

Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02482-6, published online 7 August 2023. In the version of the article initially published, in Table 1, five cancer types were mistakenly placed under incorrect groups. Invasive breast carcinoma (BRCA), Colorectal adenocarcinoma (COADREAD), Prostate adenocarcinoma (PRAD), Melanoma (MEL) and Gastrointestinal stromal tumor (GIST) now stand as individual cancer groups.

Aug 7, 2023 | nature.com | Intae Moon |Lynette M. Sholl |Kenneth L. Kehl |David R. Liu

AbstractCancer of unknown primary (CUP) is a type of cancer that cannot be traced back to its primary site and accounts for 3–5% of all cancers. Established targeted therapies are lacking for CUP, leading to generally poor outcomes. We developed OncoNPC, a machine-learning classifier trained on targeted next-generation sequencing (NGS) data from 36,445 tumors across 22 cancer types from three institutions.